Medicare utilization — DR. ELHAM ABBASI-HAFSHEJANI (M.D.)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 31,110 | 13 | $0 | $12,173 |
| J9271 | Injection, pembrolizumab, 1 mg | 21,400 | 15 | $0 | $839,641 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 10,492 | 50 | $0 | $774 |
| J1453 | Injection, fosaprepitant, 1 mg | 8,850 | 18 | $0 | $1,197 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 8,268 | 41 | $0 | $773 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·